May 14, 2018 8:15 am EDT Abeona Therapeutics Announces Appointment of Stefano Buono and Richard Van Duyne to its Board of Directors
May 11, 2018 8:15 am EDT Abeona Therapeutics Reports First Quarter 2018 Financial Results and Business Highlights
Apr 23, 2018 8:15 am EDT Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA
Apr 20, 2018 8:15 am EDT Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease
Apr 2, 2018 8:15 am EDT Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer
Mar 16, 2018 5:10 pm EDT Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights
Mar 15, 2018 8:45 am EDT Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 Disease
Feb 12, 2018 8:45 am EST Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-202 Gene Therapy Program in Infantile Batten Disease
